Inclusion Criteria:

1. Histologically confirmed aggressive B cell lymphoma;

2. New-diagnosed and untreated;

3. Age older than 70 years or older than 60 years with ECOG PS ≥ 2;

4. Understand and voluntarily sign an informed consent form, able to adhere to the study
visit schedule and other protocol requirements.

Exclusion Criteria:

1. Inadequate hepatic, nephritic and cardiac function:total bilirubin, ALT, AST,Cr more
than two fold of upper normal level. cardiac function more than Grade II;

2. Presence of Grade III nervous toxicity with two weeks;

3. HBV virus load(HBV DNA)> 1×10E5 copies/ml;

4. Concomitant malignancy other than aggressive B cell lymphoma and need to treat;

5. Concomitant with other hematologic diseases(such as leukemia,hemophilia primary
myelofibrosis) which investigator it unsuitable to be enrolled into this clinical
trial;

6. Active and severe infectious diseases;

7. Major surgery within three weeks;

8. Any potential drug abuse, medical, psychological or social conditions which may
disturb this investigation and assessment.

9. In any conditions which investigator considered ineligible for this study. 10. Known
sensitivity or allergy to investigational Product.